|
name click to compare prices |
» Shop local, ethical and at the best price on Ethishop |
|
|
|
shareholder | country | % | source |
|
year | business source |
2006 | AstraZeneca is the world's fifth-largest pharmaceutical group. | Les Echos |
|
country | address & contact : production type incentive source |
India | Bangalore : R&D Les Echos |
Mexico | Astra, MEXICO NAUCALPAN URBINA 15 PARQUE INDUSTRIAL & 5 3006906 : Sistema de Informacion de la Industria Maquiladora |
|
year name | photo position; compensation source |
2006Schweitzer, Louis | Chairman of the Board; attendance fee: 0,38 million Eu€; Capital |
|
year | employees <> | social impact : country source |
2009 | -15000 | Internal restructuring: AstraZeneca removes 15000 employment before 2013 to save 2,5 billion dollars per year.: | Les Echos |
2008 | -1400 | Internal restructuring: AstraZeneca closes its plants in Porrino (Spain), Destelbergen (Belgium) and Umea in Sweden and reduces the production of its plants in Macclesfield, United Kingdom, and Södertälje, Sweden.: | Les Echos |
2007 | -3600 | Internal restructuring: AstraZeneca toughens its reorganization plan and finally cuts 10% of its 2006 workforce. AstraZeneca will save more than 656 million euros a year from now to 2010.: | L'usine nouvelle |
2007 | -70 | Internal restructuring: FranceLes Echos | |
2007 | -3000 | Internal restructuring: AstraZeneca cuts 4,6% of its workforce, in spite of 6 billion dollars net profit in 2006.: United States of America | L'Expansion |
|
year | employees <> | social impact : country source |
|
year | country : consequences source |
2005 | brand: Seroquel : Older patients with dementia who are given antipsychotic medicines are far more likely to die prematurely than those given placebos. Most died of heart-related problems like heart failure or infections like pneumonia (FDA) | New York Times |
1999 | : Production, purchase or sale of genetically modified organisms which may cause an irreversible genetic pollution, a destruction of the biodiversity and health risks for the consumers. | The Guardian |
|
year | country : consequences source |
|
year | financial misdemeanor | sales | income | | buyback | source |
2008 |
| 31,6 | 6,1 | |   | billion US$ | Les Echos |
2006 |
| | 6 | |   | billion US$ | L'Expansion |
2005 |
Condamné par la Commission Européenne pour pratiques anticoncurrentielles. Le laboratoire a détourné des procédures administratives dans le but de protéger les ventes de son anti-ulcéreux vedette, le Losec (vendu en France sous le nom de Mopral),. A trompé plusieurs offices de brevets nationaux sur la date à laquelle il a reçu sa première autorisation de mise sur le marché, ce qui lui a permis d'obtenir une protection complémentaire dans certains pays. A détourné les règles et procédures appliquées par les agences nationales des médicaments, qui délivrent les autorisations de mise sur le marché. Il a en effet remplacé la présentation d'origine du Losec, en capsules, par des comprimés, en demandant à des agences nationales d'annuler les autorisations de mise sur le marché des premières. Ce qui a pu empêcher des importateurs d'obtenir des licences d'importation, faute d'autorisation de référence. Amende de 60 millions d'euros. |
| | | |   | | Les Echos |
2005 |
| | | | 0,6 | million shares | Cercle Finance |
2004 |
Guilty plea by AstraZeneca: collusion among drug companies and doctors to bill government health programs for free samples given as promotions |
| | | |   | | Bloomberg |
2003 |
| 18,85 | 4,2 | |   | billion US$ | Les Echos |
2002 |
| 17,84 | 2,84 | |   | billion US$ | |
2001 |
| 16,48 | 2,97 | |   | billion US$ | |
2000 |
| 18,1 | 2,54 | |   | billion US$ | |
1999 |
| 18,45 | 1,14 | |   | billion US$ | |
1998 |
| 9,37 | 1,18 | |   | billion US$ | |
1996 |
Defrauded the US healthcare system: gived free samples of cancer drugs to doctors, who then billed Medicare for the full price. |
| | | |   | | BBC News |
|
year | financial misdemeanor | sales | income | assets | buyback | source |
|
year | purpose : intermediary/lobby : institution source |
2000 | Limit the legal liability, no price control, no list of preferred drugs, hampers the approval and marketing of generic drugs, no drug imports, no limit to drug advertising… : Pharmaceutical Research and Manufacturers of America : : US government, congress, senate translate | Washington Post |
2000 | Lift the ban on bovine growth hormons, the moratorium on GMOs : EFPIA (European Federation of Pharmaceutical Industry Associations) : : European Commission translate | EFPIA |
1999 | Market access and investment protection (through WTO, GATS), avoid social and environmental rules : ICC (International Chamber of Commerce) : : WTO, GATS translate | Corporate Europe Observatory |
1998 | Regulation favorable to company's interests : Contribution to Candidate's Political Action Committee : amount: 125 thousand US$ : US President, Congress, Senate translate | Center for Responsive Politics |
|
year | purpose : intermediary/lobby : institution source |
|
year | dubious practice : image source |
2007 | Disinformation: The medical representatives of AstraZeneca incite the doctors to prescribe inexium to replace Mopral, competed with by a generic drug. The Inexium however does not bring any additional therapeutic effectiveness but its refunding by the Social security cost 300 million euros in five years to the policy-holders.: | UFC Que Choisir |
2004 | Arguable partnership: Don pour les victimes du tsunami:715 000 euros: value: Humanitaire; | AFP |
|
|
|